We believe that science is bigger than any one person. Therefore, we’ve come together from different countries and continents to work as one team. At ReHeva, we are all empowered to think differently, push scientific boundaries, challenge the status quo, and continually innovate. Our success will be what we achieve collectively. To accomplish our goals, we have assembled an experienced and highly-skilled group of industry veterans, scientists, clinicians, and leaders from around the world. Our expertise in cancer research and drug discovery serves as the foundation of the organization.
Dr. Kardan is an Associate Professor and chief of Nuclear Medicine and Molecular Imaging at the Baylor College of Medicine. He has an interest in the development and clinical translation of novel, bioimaging markers for the diagnosis and management of various malignancies.
Zeenia is a trained molecular and cell biologist with 11 years of experience in oncology. She has led and overseen ReHeva since its inception to initiating FDA Phase 1 clinical trial. During her graduate and post-doctoral training, Zeenia was awarded several prestigious national and international awards for leadership and research.
Bill is a seasoned entrepreneur with a background in technology and the travel industry. Prior to co-founding ReHeva, Bill was the founding CEO of Silvercar, Inc., a rental car company that was purchased by Audi. He also worked in the airline industry as the CEO of Skybus Airlines and was the former CEO of SystemOne.
More than 30 years of academic research experience in molecular and cell biology. Globally recognized for his research in identifying proteins that cause aging and cancer. Dr. Kaul research has been continuously funded by the National Institute in Japan. Dr. Kaul has served on several boards and advisory panels and actively participates in the peer review process for many national and international funding agencies and scientific journals. With numerous publications and patents, Dr. Kaul has been elected as a Fellow of the National Academy of Sciences, India and Indian Academy of Neuroscience, India. Dr. Kaul services as the chairman of Indian Scientists Association in Japan (ISAJ), Registered Non-Profit Organization (NPO) in Japan.
Dr. Newton has worked for 35 years in the pharmaceutical and biotech life sciences industries. He co-discovered and was the product champion of what is now the largest-selling and most-prescribed cholesterol-reducing drug in the world, atorvastatin (Lipitor®). He is currently Founder, Board Director, and Scientific Advisor at Esperion Therapeutics. Prior to his current responsibilities, Roger was SVP, Pfizer Global R&D, and Director, Esperion Therapeutics, a Pfizer, Inc. company.
Dr. Hoffman has over 35 years of product development experience. She has served as the Director of Extramural Clinical Trials of the Biological Response Modifiers Program at NCI. During her 14-year tenure at the FDA, she formed and chaired an internal FDA Botanical Working Group which developed the Botanical Drug Guidance, which the FDA finalized in 2004.
Joanna brings 15 years of experience in clinical program leadership and management in pharmaceutical and biotechnology research. She has overseen international and national multi-center clinical trials in oncology, neurology, immunology, and diagnostic imaging.
